MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

VOLUNTARY ANNOUNCEMENT ENTERING INTO A LETTER OF INTENT IN RELATION TO THE POTENTIAL DISPOSAL OF EQUITY INTEREST IN SHANGHAI MICROPORT ORTHOPEDICS CO., LTD.

This announcement is made by MicroPort Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform its shareholders and potential investors of the recent development of the Group.

THE LETTER OF INTENT

On 15 July 2026, Suzhou MicroPort Orthopedics Scientific (Group) Co., Ltd. (蘇州微創骨科學(集團)有限公司) ("**Suzhou MicroPort**"), a subsidiary of the Company, and Tinavi Medical Technologies Co., Ltd. (北京天智航醫療科技股份有限公司) ("**Tinavi**"), entered into a letter of intent (the "**Letter of Intent**") in relation to Tinavi's potential acquisition of a controlling interest in Shanghai MicroPort Orthopedics Co., Ltd. (上海微創骨科醫療科技有限公司) (the "**Target Company**", together with its subsidiaries, the "**Target Group**") from Suzhou MicroPort and other shareholders of the Target Company (the "**Potential Transaction**"), with the consideration to be paid through the issuance of new shares by Tinavi.

The Letter of Intent represents the preliminary intention of both parties in respect of the Potential Transaction only. As at the date of this announcement, negotiations with other shareholders of the Target Company are still ongoing. The parties will further negotiate the specific terms of the Potential Transaction, including, among others, the percentage of the equity interest in the Target Company to be transferred, the consideration, the issue price and the number of the shares to be issued by Tinavi, which will be set out in the formal agreement(s) in respect of the Potential Transaction (the "**Formal Agreement(s)**").

INFORMATION OF THE COMPANY

The Company is incorporated in the Cayman Islands and the shares of which are listed on the main board of The Stock Exchange of Hong Kong Limited. The Company, together with its subsidiaries, is a leading medical device group focusing on innovating, manufacturing and marketing high-end medical devices globally in a broad range of business segments including cardiovascular devices, orthopedics devices, endovascular and peripheral vascular devices, structural heart intervention and cardiac rhythm management, surgical robot and other business.

INFORMATION OF THE COUNTERPARTY

Tinavi is a joint stock limited company established in the People's Republic of China (the "**PRC**") and the shares of which are listed on the Shanghai Stock Exchange (stock code: 688277). Tinavi, together with its subsidiaries, is a leading company in the orthopedic surgical robotics industry of the PRC, focusing on independent innovation, large-scale production, professional marketing and high-quality clinical application of orthopedic surgical robots and related technologies. Tinavi is the first in the world to launch a surgical robot platform covering the three major orthopedic fields, namely spine, joints, and trauma, enabling a single platform to address multiple indications. Its products consistently rank first in the domestic market in terms of both hospital coverage and procedure volume, and as of the end of the first quarter of 2026, the clinical application of its core product, TiRobot series of orthopedic surgical robots, had expanded to more than 200 medical institutions across 31 provinces, autonomous regions, and municipalities nationwide, with the number of surgeries performed exceeding 160,000.

INFORMATION OF THE TARGET GROUP

As at the date of the Letter of Intent, the Target Company, in which Suzhou MicroPort holds an 82.29% equity interest, is accounted for as a subsidiary of the Company. The Target Company is the core operating entity for the Group's international (non-China) orthopedics business. The Target Group is principally engaged in the hip and knee orthopedic reconstruction business in overseas markets such as the United States, Japan and Europe. The Target Group has years of extensive expertise in the orthopedic field, focusing on the research, development, production, and sales of high-quality, innovative hip and knee joint products that have been thoroughly clinically validated. It has established a mature, large-scale overseas sales network. Its representative product, medial pivot knee prostheses, has accumulated more than 20 years of clinical application experience. According to research findings published in The Knee[(1)], the Target Group's medial pivot knee prostheses achieved a 17-year cumulative prosthesis retention rate of 98.8% and a patient satisfaction rate of 95%.

STRATEGIC SIGNIFICANCE OF THE POTENTIAL TRANSACTION

1. Creation of synergistic effect through the strategic collaboration between the Target Group and Tinavi

The Target Group possesses a line of high-performance joint replacement prostheses products and well-established marketing channels developed over many years of serving overseas orthopedic

(1) A long term clinical outcome of the Medial Pivot Knee Arthroplasty System. George A.Macheras, et al. The Knee. 2017. 24(2): 447-453

markets, while Tinavi has deep expertise and a leading position in the field of orthopedic surgical robots. The business synergies, strategies, and long-term goals of both parties are highly aligned. The Potential Transaction is expected to integrate their respective strengths and resources to form a powerful partnership, unleashing synergies far exceeding those achievable through independent operations and helping both parties achieve long-term performance growth.

2. **Achieving long-term investment value in the Target Group through strategic collaborations**

   Through the Potential Transaction, both parties are expected to achieve business integration and gradually realise synergies, thereby continuously enhancing the business scale, profitability and risk resilience of Tinavi and the Target Group and increasing the long-term investment value of the Group in the Target Group's business.

GENERAL

The Board wishes to emphasise that the Potential Transaction is in the planning stage, and it is subject to, among other things, (i) the successful conclusion of commercial negotiations on the terms of the Potential Transaction between the parties; (ii) the completion of the due diligence to be carried out by the relevant party; (iii) the entering into of the Formal Agreement(s); and (iv) the obtaining of the requisite internal and regulatory approvals, including but not limited to the approvals, filings and/or registrations required under the applicable PRC laws and regulations. There is no assurance that the Potential Transaction will materialise or as to the final terms thereof.

The Potential Transaction, if materialised, may constitute a notifiable transaction of the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The Company will comply with the applicable requirements under the Listing Rules as and when appropriate, and further announcement(s) will be made by the Company as and when appropriate in compliance with the Listing Rules.

As the Potential Transaction may or may not proceed, shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the People's Republic of China, 15 July 2026

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu, Mr. Chunyang Shao and Dr. Yingyao Chen.

* *For identification purpose only*